Cancers of unknown primary origin: current perspectives and future therapeutic strategies by Stella, Giulia Maria et al.
REVIEW Open Access
Cancers of unknown primary origin: current
perspectives and future therapeutic strategies
Giulia Maria Stella
1,2*, Rebecca Senetta
3, Adele Cassenti
3, Margherita Ronco
3 and Paola Cassoni
3
Abstract
It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes,
rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly
detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and
accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic
evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict
the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early
occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management
of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology
and pathology, which will lead to successful tailored therapeutic options.
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Introduction
Cancer of unknown primary (CUP) origin defines meta-
static tumour detected when the site of primary origin
cannot be identified based on clinical history, complete
physical examination, routine laboratory tests, imaging
and radio-metabolic techniques and careful review of
histological specimens. Although this malignant syn-
drome accounts for 3-5% of all cancer diagnosis, the
majority of patients still lacks effective therapeutic regi-
mens [1] CUP clinical presentation is extremely hetero-
geneous: about 15-20% of CUP patients can be assigned
to favourable subsets whereas the others share a very
aggressive potential and unpredictable pattern of meta-
static spread. The largest group of these tumours is
refractory to standard chemotherapy and the median
survival of CUP patients is very low.
There is poor consensus on the extent of diagnostic
evaluations in front of metastatic cancers without a pri-
mary mass. At the present immunohistochemistry (IHC)
is often the only standard method by which a putative
primary origin can be postulated. Nevertheless, recent
improvements in molecular diagnostics will allow a
most appropriate pathological classification of early
metastases. However the most relevant approach to
CUP is related to the understanding of the biology
which drives precocious metastatic spreading.
This review summarizes the current knowledge on
pathological features, diagnostic tools and biological
behaviour of CUPs, mainly focusing on the next future
therapeutic implications.
CUP: definition, epidemiology and clinical
approach
Almost one third of advanced tumours presents with
metastases at time of diagnosis. In the majority of cases
the organ site of primary lesion becomes shortly evident
after clinical, pathological and radio-metabolic evalua-
tions. The other cases can be roughly defined as metas-
tases of unknown primary origin. Indeed this definition
includes two groups of tumours: 1) the cases in which
the primary site might be postulated at least by their
ICH profile; 2) the metastatic lesions which remain
really ‘orphan’ even after an exhaustive IHC screening.
Although the separation into two groups based on the
IHC profile could be somehow artificial, it may be
important for patient management and the choice of
initial therapeutic regimen. * Correspondence: giulia.stella@ircc.it
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about 3-5% of all cancer diagnosis [2]. The annual age-
adjusted incidence per 100,000 population in USA is 7-
12 cases; in Australia 18-19 cases and in the Nether-
lands 5.3-6.7 cases [3]; however it must be kept in con-
sideration that the incidence might be higher since
some CUPs patients are classified for pragmatic clinical
reasons as ‘known primary’ even if their diagnosis is
uncertain. The median age at diagnosis is reported to be
60 years and the occurrence is slightly higher in males.
In some instances, although the metastatic pattern is
often unpredictable, the site of primary origin can be
found during lifetime or autopsy: it is generally a small
nodule often localized in the lungs or in the bilio-pan-
creatic tract [4].
In the early 1970s some researchers argued that diag-
nosis of cancer of unknown primary origin could only
be made if the primary tumour was not found at
autopsy [5]. At the present, as suggested by Interna-
tional Guidelines (http://www.nccn.org,http://www.
esmo.org), all the patients who present with a metastatic
cancer suspected to be of unknown primary should have
an accurate physical examination, complete laboratory
tests and a whole body imaging study (Computed
Tomography - CT - scan and Positron Emission Tomo-
graphy - PET). Besides, female patients have to undergo
mammography and vaginal ultrasound (US) scan,
whereas prostate US scan is required in males. Various
endoscopic procedures (laryngoscopy, bronchoscopy,
gastroscopy, colonoscopy or cystoscopy) should be
ordered in selective cases, based on several clinical fac-
tors such as patients’ relevant symptoms and/or signs,
physical examination findings, sites of metastases, occult
blood in the stool, laboratory findings as well as any
other factor which would prompt endoscopies. More
than 50% of CUP patients present with multiple sites of
involvement while the rest have a single site, most com-
monly liver, bone, lung or lymph nodes [6].
CUP patients are classified into subgroups and specific
risk categories according to the organs involved (disease
stage) and histology in order to optimize patient man-
agement [7]. A minority (15-20%) of patients belongs to
the subset at more favourable prognosis: these patients
harbour the most differentiated and chemosensitive
tumors and have the longest survival rates. Unfortu-
nately the majority of cases do not belong to any speci-
fic category. These cases have the worst prognosis,
displaying a substantial resistance to therapy. Unfavour-
able predictor factors are related to diagnosis of: adeno-
carcinoma metastatic to liver, non-papillary malignant
ascites, multiple cerebral metastases, multiple lung/
pleural metastases, systemic bone disease. Better prog-
nosis is, on the other hand, related to: poorly differen-
tiated carcinoma with midline-distribution, papillary
adenocarcinoma of peritoneal cavity (in women), adeno-
carcinoma involving only axillary lymph nodes (in
women), squamous cell carcinoma involving cervical
lymph nodes, isolated malignant adenopathy, poorly dif-
ferentiated neuro-endocrine carcinoma, single small and
potentially resectable tumour [2,6]. Notably, it seems
that CUP survivors have a higher risk of developing
many subsequent cancers [8]. The overall prognosis of
CUP patients is generally very poor with a median survi-
val of 4-12 months, with about 50% of patients alive at 1
year and about 10% at 5 years from diagnosis [9]. Ther-
apy is currently designed on the bases of clinical-patho-
logical investigations and according to disease staging
and risk assessment; at the present the optimal che-
motherapeutic regimens remains to be clarified and the
most commonly used regimens contain platinum [1].
Pathologic presentation and analysis
Cancer can arise in any tissue of the body. In the vast
majority of cases, the first step in cancer onset is the
growth of a primary lesion; only later a metastatic clone
acquires the biological properties required to detach
from the mass, invade lymphatic or blood vessels and
eventually colonize distant organs. Nevertheless some
exceptions from this behaviour might be underlined.
Sometimes tumours arise as multiple primary lesions.
They could be: i) synchronous tumours and can display
d i f f e r e n th i s t o l o g yo rs h a r et h es a m eh i s t o l o g yb u tb e
anatomically separated; ii) metachronous nodules with
the same histology, but temporarily separated each
other. Multiple nodules can also identify satellite
nodules of a primary lesion if they share the histology of
the primary tumor and are spatially separated within the
same organ. Finally multiple neoplastic nodules might
be metastases, which have spread from a primary tumor
and grown with a spatial and temporal (< 2 years) inter-
val from it. From the anatomic perspective, metastasis
can leave the primary site through a cavity (e.g. from
lungs to the pleural cavity or from colon to perito-
neum); by lymphatic spreading or through blood vessels.
Cancer cells can even migrate across the endothelium,
the basement membrane or along neurons [10-13]. In
general metastatic cells maintain the histologic features
of the tissue from which they derive, even in case of
upfront metastatic cancers. However, in a number of
cases, cancer cells appear as multiple nodules which do
not display morphology and properties referable to the
tissue/organ in which they are arising or cannot be
related to any suspected distant primary site. The latter
identify cancers of unknown primary (CUP) origin
(Figure 1).
When CUP is suspected, the diagnostic algorithm fol-
lowed by pathologists has to be–at the same time–strict
and extensive. The vast majority of CUPs are
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morphology, CUP can be classified as: i) well, moder-
ately or poorly differentiated adenocarcinomas; ii) squa-
mous cell carcinomas; iii) poorly differentiated
carcinomas, iv) carcinomas with neuroendocrine differ-
entiation; v) undifferentiated cancers. Adenocarcinomas
of unknown primary are the most frequently diagnosed.
In such settings, immunohistochemistry is the only stan-
dard test which could be the determining factor to sug-
gest the primary origin of the lesion. Several
immunohistochemical markers have been proposed to
predict the site of the primary tumor. As recently sug-
gested by Greco FA et al. [14] the screening panel
might include citokeratins (CK-7; CK-20), TTF-1;
breast/ovarian markers, HEPAR-1, renal cell, placental
alkaline phosphatase/OCT-4, WT-1/PAX8, synaptophi-
sin and chromogranin. IHC accurately predicts a (single)
primary in ~ 35/40% of early metastatic cancers [6]. It
has been demonstrated that panels of markers are
superior to single biomarkers in identifying the primary
site, at least in adenocarcinomas. Dennis JL and coll.
[15] provided correct primary site identification in 88%
of cases of metastatic adenocarcinoma applying an
immunohistochemical diagnostic algorithm including 10
immunohistochemical markers. However it should be
n o t e dt h a tt h e s es t u d i e sw e r ed o n ei np a t i e n t sw i t h
known metastatic cancers, rather than in patients with
CUP. Thus, their findings, although important, may not
be entirely analogous to patients with unknown primary
cancer. Besides, the pathologic evaluation is in the vast
majority of cases performed on formalin-fixed paraffin-
embedded (FFPE) small sized samples, mainly derived
from bioptic procedures. Besides, the choice of IHC
panel deeply influences subsequent diagnosis [16,17].
Moreover IHC lacks of specificity and sensitivity in
staining some primary tumors, such as upper gastroin-
testinal cancers (gastro-esophageal and pancreatico-bili-
ary tumor). As a consequence, in a number of cases the
I H Cm a r k e r sp r o f i l em a yo n l ys u g g e s tad i f f e r e n t i a l
diagnosis rather than indicate a conclusive single
diagnosis.
In conclusion, the diagnostic procedure begins if
necessary by determining the cell lineage (epithelial,
melanocytic, lymphoid, mesenchymal, germinal cells)
with the aid of appropriate markers; the IHC panel will
be then determined coherently. Here we propose a
hypothetical ideal IHC diagnostic algorithm for screen-
ing and issuing towards tumor primary, which may be
used once the tumor has been confirmed to be a carci-
noma (Figure 2). It should be remarked that, although
complete and concise, realistically, this approach could
not be recommended in all patients. The clinical cir-
cumstances, including the patient’sg e n d e r ,s i t eo f
metastasis, histologic appearance of their tumor and the
screening immunohistochemistry of CK-7, CK-20, TTF-
1 and CDX-2 might be considered as first step and sub-
sequent staining needs to be individualized, based upon
patient’ s clinical pathologic setting.
There are few reports focusing on the validation of the
predictive value of the immunophenotype in CUPs.
From this perspective, classical pathologic approach can
be integrated by molecular biology and gene expression
profiling studies. In 2008 Horling H and coll. [18]
showed that the IHC prediction of primary was consis-
tent with the molecular profiling in a series of adenocar-
cinoma of unknown primary.
In summary, in some cases IHC algorithms can allow
the identification of a primary site with adequate accu-
racy but, at the present, there are not enough precise
knowledge to definitely distinguish two different groups,
those with and without IHC-solved primary. As a conse-
quence, unless patients have a clinically defined and
anatomically recognized primary site–discovered at the
time of the workup or later in the course of their dis-
ease, have CUP. It means that–at the present–there is
no enough precise knowledge to state that those cancers
without a strong IHC single diagnosis are definitely dif-
ferent from the others. However, a precise and recog-
nized immunohistochemical profile may lead to
appropriate treatment in individual patient’s settings.
This approach has been clearly supported by Varad-
hachary GR and coll. [19] and more recently by Greco
FA and Hainsworth JD [20]: in both cases, authors
described a CUP featuring the CDX-2 and CK20 +, CK-
7 staining profile and they defined it as a ‘colon cancer
profile CUP (CCP-CUP)’. Importantly, it has been shown
that this subset of patients better responds and seems to
have a superior outcome when treated with site-specific
therapy.
Figure 1 Tacking the primary: from multiple malignant
nodules to CUPs.
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Detection of the primary tumor may optimize treatment
planning, which, in turn, may improve patient prognosis.
This goal might be considered in front of a suspect of
metastatic cancers of occult primary. Since the unknown
primary mass can be located anywhere in the body, a
cross-sectional whole-body imaging modality is the
proper method to look for a primary site. Ultrasound is
a fairly quick and easy procedure that doesn’tu s er a d i a -
tion, which is why it is often one of the first tests done
if an internal mass is suspected; computed tomography
(CT) and magnetic resonance (MRI) thus represent the
imaging studies most used in clinical practice to dissect
the whole body. The combination of 18 F-fluorodeoxy-
glucose (FDG) positron emission tomography (FDG-
PET) and CT has gained wide acceptance, especially if
the primary tumor is unknown. It should be noted that
small lesions or pathological changes in normal-sized
tissues can be missed by CT and MRI; this is especially
relevant in CUP setting in which the primary tumor is
supposed to be a small lesion [21]. From this perspec-
tive, positron emission tomography using the radiotracer
18 F-fluoro-2-deoxyglucose, is the leading approach
since it provides functional and metabolic information
with an excellent lesion vs background ratio. Notably,
studies of unknown primary malignancies are among
the most appropriate indications for PET, according to
international nuclear medicine guidelines [22]. Integra-
tion of PET/CT scanner (equipped with a 16- to 64-sec-
tion multidetector-row CT unit) is rapidly replacing the
PET study alone and is at the present the preferred
method of choice for the detection of primary tumors in
patients with CUP. Notably, PET/CT imaging is known
to have a good sensitivity and specificity, mainly in head
and neck and lung cancers [23]. A true positive result is
considered when the imaging-suggested putative pri-
mary is subsequently confirmed through biopsy. On the
other hand, a false negative result is considered if the
primary tumor is detected in as i t et h a ti sn e g a t i v eo n
the imaging technique. A recent meta-analysis [24]
showed that, overall, FDG-PET/CT is able to detect 37%
of primary tumors in patients with CUP, with both sen-
sitivity and specificity of 84%. Although data as a whole
are encouraging it should be noted that cohorts of CUP
patients analyzed in each study are extremely mixed and
heterogeneous (Table 1).
In conclusion the diagnostic challenge for PET/CT is to
minimize the false negative in tracking the primary
tumor. FDG is a nonspecific radiotracer with can accu-
mulate also in no-malignant areas of increased glycolysis,
such as inflammatory areas. A number of radiotracers are
under investigation including compounds that can mark
hypoxia, angiogenesis and apoptosis in tumors. Advances
in PET technology and the integration of PET/MRI as
Figure 2 Diagnostic algorithm to characterize metastatic adenocarcinoma from unknown primary.( C K :c y t o k e r a t i n ;T T F 1 :t h y r o i d
transcription factor 1; ER: estrogen receptor; CA125: cancer antigen 125; tireo: tireoglobulin; VIM: vimentin; PSA: prostate specific antigen)
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are expected to improve the management of CUP
patients.
Molecular profiling for the identification of the
primary tissue-of-origin
Despite the large number of patients diagnosed with
carcinoma of unknown primary site of origin, innovative
and individualized approaches to managing these
patients have laggedb e h i n dm a n yo t h e rs o l i dt u m o r s .
At the present great efforts are directed to take advan-
tages from the new microarrays technology to predict
the tissue-of-origin (ToO) of CUP. This approach is
eventually driven by the hypothesis that the knowledge
of the putative primary could help customizing therapy
and thereby improve clinical outcome.
Several methods for identifying CUP samples based on
their gene expression profiles have been developed.
Talantov D and coll. [48] and Varadhachary GR and
coll. [49] have presented an RT-PCR based method that
measures the expression of 10 signature genes. Ma XJ
and coll. [50] proposed a similar method based on 92
genes, which resulted in an overall accuracy of 82%
among 39 cancer types. Tothill RW and coll. [51]
presented a support vector machine based method for
classifying cancer types, and selected 79 genes for an
RT-PCR test reaching a total accuracy of 89% but only
among 13 cancer types. Rosenfeld N and coll. [52]
applied a similar approach, but instead of measuring tra-
ditional gene expression, they looked at miRNA expres-
sion to classify CUP samples. For a majority of the
samples, they achieved a ~90% classification accuracy.
There are currently several commercial tests available
with gene expression-based assays that classify tumors
of unknown or uncertain origin: Pathwork [microarray
for messenger RNA (mRNA)], Rosetta Genomics and
Prometheus (RT-PCR for microRNA), and bioTheranos-
tics (RT-PCR for mRNA). All tests claim prediction
accuracies in known primary cancers between 80% and
90% [14]. However, each test has different specimen
requirements and a wide range in their ability to identify
cancer types/subtypes (15-54 types/subtypes). In general,
a clinically viable test needs to be compatible with FFPE
tissues with low numbers of tumor cells and to have the
ability to discriminate large number of tumor types
since metastatic cancers can arise from many cancer
types and primary tumor sites. More recently Varad-
hachary GR and coll. [53] showed in a perspective study
Table 1 Predictive values of PET in tracking the primary site in case of early metastatic cancers
Match PET/histology in identification of the
primary lesion
Total examined
cases
Predictive value of PET% (n of
patients)
False positive cases% (n of
patients)
Reference
Failed 1 –— [25]
Partial 23 56,5 (13) — [26]
Partial 39 27 (6) 2.5 (1) [27]
Failed 18 –— [28]
Partial 20 11(55) 5 (1) [29]
Partial 149 24.8 (37) 8.7 (13) [30]
Failed 20 –— [31]
Partial 51 9.6 (5) — [32]
Partial 77 36.4 (28) 1.2(1) [33]
Partial 24 37.5 (9) 12.5 (3) [34]
Complete 1 1 — [35]
Partial 59 59 (35) — [36]
Partial 44 31.8 (14) 11.3 (1) [37]
Partial 47 14.8 (7) 27.6(13) [38]
Partial 13 7 (54) — [39]
Partial 43 55.8 (24) 2.3 (1) [40]
Partial 67 53.7 (36) 1. 49 (1) [41]
Partial 430 31.4 (135) 3.9 (17) [42]
Partial 60 30 (18) 21.6 (13) [43]
Partial 39 26 (10) — [44]
Partial 15 20 (4) 6.6 (1) [45]
Partial 14 40 (7) 7.1 (1) [46]
Partial 38 53 (20) 2.6 (1) [47]
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assay in a high percentage (84%) of metastatic cancers.
Authors’ conclusion suggested that microRNA assay
may be most helpful in guiding management when IHC
studies are unconclusive or provides a large differential
diagnosis. Therefore, where applicable, those tests may
be intended as complement to IHC to provide an multi-
disciplinary network for a most appropriate clinical
management of CUP patients. Similar conclusions have
been reached by Ferracin M and coll. [54] that demon-
strated that FFPE samples can be used to reveal the
ToO of metastatic cancer by using miRNA expression
profile and suggested that this approach could provide
useful indications for CUPs. It has also been documen-
ted that Pathwork test can be adequately performed on
FFPE cell blocks from cytologic body fluid specimens
material and can be used in the identification of ToO in
case of metastases of unknown primary [55]. In all the
reported works, authors argue that the availability of
ToO holds promise for the increasing individualization
of therapy for CUP patients [20]. Authors’ ultimate goal
is to provide a helpful framework where profiling and
pathology are integrated in a cost and clinically effective
algorithm with a positive impact on patient survival and
quality of life. Molecular profiling for the identification
of the ToO is a promising technique to improve the site
of origin diagnosis in CUP patients, which could be
exploited in the clinical practice. Interestingly, prospec-
tive clinical trials are ongoing to determine whether
treatment based on molecular profiling can improve
CUP patient outcomes. A major issue is to determine if
CUP patients respond similarly to the corresponding
subsets of patients with known primary when treated
with site-specific therapy, based upon IHC profile and/
or molecular profiling assay. Besides, gene expression
assays will be promising for diagnosis and hence ther-
apy, in those cases displaying inconclusive IHC profile.
Current therapeutic approach to CUPs
Surgical management of metastases of unknown primary
is generally related to limited/single disease. Neverthe-
less, a recent report demonstrated for the first time that
surgery in case of multiple sites of spinal disease did not
influence survival; whereas the presence of extraspinal
disease had a negative impact [56]. However since CUP
syndrome mainly presents with advanced disease sys-
temic therapy is the most frequent approach.
The continuing development of new therapies targeted
to the various cancer types makes mandatory the identi-
fication of the primary tumor and–as discussed above–
many efforts are now directed to integrate molecular
based medicine and clinical practice to assign a primary
as soon as possible after diagnosis of metastases of
occult primary origin. However in case of CUP
diagnosis, therapy regimes lack to be specific and, in the
vast majority of cases, chemotherapy regimens include
platinum, an alkylating agent which is effectively used
for the management of patients with the most common
solid tumors. In those settings, treatment may only help
to control metastatic disease for a time and to improve
patient symptoms. Overall clinical prognostic markers
include: patient’s age, gender, weight loss and perfor-
mance status; histopatology and tumor burden, location
and number of metastatic sites; as well as serum bio-
markers [2]. In addition, the French CUP Group (GEF-
CAPI) developed a simple prognostic index for patients
with CUP, in which favorable prognostic factors
included a performance status < 2 and normal serum
LDH levels [57]. Several other algorithms are under
investigation, with the aim to help clinicians involved in
CUP patients care. Interestingly, the survival of CUP
patients who are enrolled in clinical trials significantly
higher (6-10 months) if compared to that of unselected
CUP patients who are not enrolled in clinical trials (2-3
months) [58].
For adequate therapeuticg u i d a n c eC U Pe n t i t i e s
should be categorized into favorable or unfavorable sub-
sets [59]. In the recently published ESMO guidelines [1],
it has been clearly stated that treatment has to be tai-
lored on an individual basis according to the clinical-
pathological subset of distinct prognosis in which the
patient belongs. About 10-15% of CUP patients of the
favorable risk subsets should be treated similarly to
patients with equivalent known primary tumors with
metastatic dissemination. As discussed above, patients
who belong to these subcategories have a better prog-
nosis and undergo specific recommended treatments.
Indeed in those cases, retrospective analyses have shown
that patients’outcome displays no substantial differences
from those with metastatic tumors of known primary.
On the other hand, patients with poor-risk CUP have a
dismal prognosis despite management with a variety of
chemotherapeutic combinations in small clinical studies.
Notably, no superior efficacy has been proven–till now–
with respect to any of the tested schedules incorporating
platinum, taxanes or third generation compounds [60].
Carboplatin plus paclitaxel combination chemotherapy
has been reported to be effective in patients with predo-
minantly nodal/pleural metastases of unknown primary
carcinoma and in women with peritoneal carcinomatosis
but showed lower benefits in patients affected by liver,
bone or multi-metastatic disease [61]. Similar results
were obtained by Park YH and coll. in 2004 [62] whose
study evaluated the efficacy and toxicity of combined
paclitaxel and cisplatin chemotherapy in a subset of
CUP patients, mainly affected by adenocarcinomas. In
this phase II study the median survival was 11 months
whereas the median time to progression was 4 months.
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demonstrating that combination docetaxel carboplatin is
a safe and effective palliative option for CUP patients
[63]. Also combinatorial triplets with gemcitabine or
etoposide, carboplatin, and paclitaxel seem to be toler-
able treatment for CUP patients [64,65]. A recently
closed phase II trial evaluated the efficacy and toxicity
of the combination of paclitaxel, carboplatin, bevacizu-
mab, and erlotinib in the first-line treatment of CUP
patients [66]. All the enrolled patients received the four
drugs and treatment cycles were repeated every 21 days.
When carboplatin/paclitaxel were discontinued, bevaci-
zumab/erlotinib were continued until tumor progres-
sion. This empiric drugs combination allowed a median
progression-free survival time of 8 months, with 38% of
patients being progression free at 1 year. The median
survival time and 2-year overall survival rates were 12.6
months and 27%, respectively; toxicity profile was well
tolerated. Randomized prospective trials proving that
any form of chemotherapy improves the survival of CUP
patients with disseminated adeno–or undifferentiated
carcinoma over best supportive care alone are still lack-
ing. Nevertheless platinum-based combination schedules
represent the first line approach to CUP treatment and
because of the lower toxicity of carboplatin as compared
to cisplatin, the favored regimen is carboplatin/pacli-
taxel. With this combination, response rates of 30-40%
and a 2-year survival rate of 20-25% can be achieved if
administered as first-line therapy [67]. Few data are
available about second-line chemotherapy in CUP
patients who already received platinum-based first-line
treatment. Although it remains unclear whether second-
line chemotherapy might contribute to a survival benefit
in patients with CUP, patients who show a favorable
response to first-line chemotherapy appear to be likely
to benefit from second-line chemotherapy [68]. Che-
motherapy regimens evaluated include the combination
of oxaliplatin and capecitabine which has been found to
have activity as salvage treatment for patients with CUP,
mainly in those feature a so called ‘colon cancer profile-
CUP’ [69].
Radiotherapy is a conventional therapeutic approach
in case of cervical lymphnodes metastases of unknown
origin, not only for unresectable disease but for a com-
prehensive treatment of the whole neck. Indeed neck
dissection is not always necessary; for instance, it is not
necessary for N1 disease [70]. Intensity modulated radia-
tion therapy (IMRT) can produce excellent outcomes
without relevant long term complications [71]. Definitive
IMRT to 50-56 Gy followed by neck dissection seems to
result in excellent nodal control and overall and disease-
free survival, with acceptable toxicity for patients with
localized non-bulky disease without extracapsular
spread, T0N1 or non-bulky T0N2a stages [72]. Relapse
occurred infrequently in patients treated with excisional
biopsies and postoperative radiotherapy. These results
appear consistent with those expected for patients with
advanced neck disease and a known primary site [73].
In summary results from chemotherapy and radiother-
apy on CUP patients do not exclude them from studies
aiming to improve their outcomes. Indeed, in the last
decade it has been largely shown that cancers belonging
to the same tissue/organ do not respond to treatment in
the same way, and response to treatment lies inside
their genome: presence or absence of specific genetic
lesions (either mutations or amplifications) can really
predict responses to therapy. Ultimately a mutational
profile, rather than prediction of ToO, could be useful
to treat patients with targeted therapies. Steady colla-
boration and fluid communication between oncologists,
pathologists and molecular biologists is a clear priority
for the correct interpretation of tests and the persona-
lized approach required by each individual CUP case.
Work in multidisciplinary teams will result in significant
changes in the diagnosis and treatment of these patients
CUP: unknown primary or unknown biology?
Metastatic spread is generally considered the final step
of tumor progression and it clinically sets up the
worse level of the cancer staging system. According to
this model, the early cancer diagnosis is the one able
to detect a single localized tumor mass which is still
susceptible of surgical exeresis. However, as discussed
above, in 3-5% of all human cancers distant dissemi-
nation arises at an early stage of tumor progression,
so that unexpected metastatic phenotype can over-
come on the primary lesion’sg r o w t h .I ns o m eo f
t h o s ec a s e st h ep u t a t i v ep r i m a r yc a nb ed e t e c t e db y
routine IHC stains or at least through gene expression
profiling. On the contrary, in some instances morphol-
ogy, imaging and molecular predictive assays are ‘non-
contributory’: only these samples could be correctly
defined as CUPs.
Thus, there are at least two different hypotheses which
can be involved in CUP biology: i) the first suggests that
CUPs are heterogeneous group of site-specific tumors
which share the properties of the small primary from
which derive; ii) the second regards to CUP as to a dis-
tinct entity with a specific genetic asset. It is clearly evi-
dent that the biological and genetic enigma that could
be related to CUPs is enclosed in the molecular
mechanisms that speed up distant metastatization so
that to confer to the primary lesion a status comparable
to dormancy. In other words, it is conceivable that
CUPs are a distinct biological entity involving specific
genetic and phenotypic alterations, although at the pre-
sent there are no known and validate molecular features
to clearly distinguish these cancers. This observation is
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performed on a CUP cohort from the Swedish Family
Cancer Database. This study showed that CUPs cluster
with families of kidney, lung, and colorectal cancers and
suggested a marked genetic basis in the onset of the
syndrome [74].
A wide variety of chromosomal abnormalities have
been described in CUPs: aberration of chromosome 1, 6,
7 and 11 are the most frequently reported [75]. Aneu-
ploidy has been seen in 70% of adenocarcinomas of
unknown primary: no relationship has been found with
the pattern of metastatic spread or the overall survival
[76]. Overall data on chromosomal abnormalities can be
considered similar to those reported in case of cancers
with known primary.
With respect to the oncogenic molecular asset of
CUP, several studies have evaluated the expression and
the mutational status of both oncogenes and tumor sup-
pressor genes. Unexpectedly–although few studies are
available–lesions of the key players know to drive the
vast majority of human cancer cannot be documented
in CUPs. Expression of c-myc, KRAS, HER2 has been
studied by IHC in a series of 26 CUP cases and was pre-
sent in less than one third of samples [77]. Nevertheless
this observation does not allow a clear classification of
CUPs. Indeed KRAS alterations, for example, are present
in just about 30% of cases of human cancer as a whole
and therefore, no significant differences seem to exist
between the latter and CUP in this perspective.
Interestingly immunohistochemistry studies demon-
strated that EGFR is frequently expressed in CUPs,
whereas c-KIT and HER2/neu are infrequently activated.
Notably no significant association has been established
between EGFR expression level and patients prognosis
[78].
The EGFR oncogene seems to be infrequently mutated
(1% data by Sanger Institute Catalogue of Somatic
Mutations in Cancer–COSMIC–http://www.sanger.ac.
uk/cosmic) in CUP whereas the intron 1 cytosine-ade-
nosine (CA) repeat has been reported [79] to be
increased in absence of correlation with patients survival
and prognosis. Previous observations [80] also demon-
strate that p53 mutations rarely occur in CUPs, thus
suggesting a minor role of the protein in CUP onset.
Precocious undifferentiated neoplastic spread is the
hallmark of CUP and this fact represents a strong ratio-
nale to investigate molecular pathways involved in meta-
static process. Very recently Koo JS et al. [81] showed
that hypoxia-related proteins are expressed in nodal
squamous cell metastases of head and neck of unknown
primary. The Glut-1, HIF1a, and COX2 expression level
seems to be related to a worse patient prognosis.
Metastasis follows the inappropriate activation of a
genetic program termed ‘invasive growth’ (or epithelial-
mesenchymal transition), which is a physiological process
that occurs during embryonic development and post-
natal organ regeneration [82]. Burgeoning evidence indi-
cates that invasive growth is executed by stem and pro-
genitor cells, and is usurped by cancer stem cells. The
MET proto-oncogene, which is expressed in both stem
and cancer cells, is a key regulator of invasive growth
[83]. MET encodes the tyrosine-kinase receptor for “Scat-
ter Factor”, a sensor of adverse microenvironmental con-
ditions (such as hypoxia [84] and ionizing radiations
[85]) and drives cell invasion and metastasis through the
transcriptional activation of the ‘invasive growth signa-
ture’, a genetic program including cell scattering, inva-
sion, protection from apoptosis and angiogenesis [86]. In
human cancers, MET activation generally occurs as a late
event, mainly consequent to receptor overexpression or
gene amplification. Somatic point mutations are rarely
found, accounting for no more than 3-4% of unselected
primary cancers (data from by Sanger Institute Catalogue
of Somatic Mutations in Cancer–COSMIC–http://www.
sanger.ac.uk/cosmic).
Several strategies to block the activation of MET are
under development, such as the use of tyrosine kinase
inhibitors or monoclonal antibodies and some of these
compounds have already been used in clinical trials [87].
We have recently demonstrated [88], by a screening of
about 50 CUP patients for occurrence of MET somatic
mutations, an extremely high MET mutational incidence
(about 15%, vs. the 1-3% of the general cancer popula-
tion), in the absence of high mutational background.
Nucleotide changes found clustered either in the kinase
domain or in the extracellular semaphorin domain.
Mutated receptors were functional and sustained the
transformed phenotype, suggesting that MET activating
mutations are genetic markers associated with the CUP
syndrome. Therefore, MET mutation may as well reflect
either differentiation grade and/or organ of origin. In
this respect a preferential expression of MET in cancer
stem cells has been postulated [83].
Conclusions
Metastases are defined as macroscopic lesions which
develop far, through blood or lymphatic vessels from
the primary tumor: they are generally resistant to ther-
apy and eventually lead patients to death. The molecular
and cellular mechanisms which drive the metastatic
spread are the topic of constant debate and scientific
research due to the potential implications for cancer
patients’ prognosis. The process of metastases might
begin before the growth of the primary mass. Recent
evidence suggests that tumor cells might start condition-
ing for distant tissues colonization through the estab-
lishment of a so called ‘pro-metastatic’ niche [89]. Early
metastatic dissemination is reflected in the clinical
Stella et al. Journal of Translational Medicine 2012, 10:12
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C U P si d e n t i f yav e r ya g g r essive pathology which–at the
present- is still lacking for appropriate therapies. Indeed
these tragic cases may be described as not only of
unknown origin with respect to the organ site but also
as of unknown pathogenesis. Despite many studies are
focused on tracking their putative origin, the real
enigma represented by CUPs is related to their own bio-
logical and genetic setting. Besides, growing evidence
sustains that rationale for personalized targeted thera-
pies is inside the tumors’ genome rather than in their
tissue of origin. Certainly this is true for all advanced
cancers and not specifically for CUPs.
This ideal of personalized oncology has not been
reached for most patients and the clinical reality at this
time is that at least some CUP patients may be treated
with more effective by recognizing their tissue of origin.
Patients with advanced cancer whether the primary site
is known or not, may eventually be treated based upon
specific genomic abnormalities that are discovered in
their cancer cells. This is already occurring in some
instances. However, knowing the tissue of origin
remains an immediate important factor in determining
therapy for most patients with advanced cancer.
Nevertheless, further studies should be addressed to
deeper investigate the molecular profile of CUPs. Preli-
minary results suggest a role for MET somatic mutations
as driving force in CUP syndrome and put MET among
the most promising therapeutic targets. Main address
should be also focused on the potential role of the cancer
stem cells compartment. Data should be collected to
characterize the role played by undifferentiated cancer
cells in tumor dissemination and their interaction with
surrounding stroma to define molecular markers able to
detect cancers displaying occult disseminative potential.
This approach will lead to the creation of a new sensitive
platform that might select an otherwise heterogeneous
group of patients, such as that of patients presenting with
metastatic cancers of unknown primary site of origin.
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